Increased P-35, EBI3 Transcripts and Other Treg Markers in Peripheral Blood Mononuclear Cells of Breast Cancer Patients with Different clinical Stages

Maryam Hamidinia ^1,2, Mehri Ghafourian Boroujerdnia ¹, Abdolhassan Talaiezadeh ^2,3, Ghasem Solgi ⁴, Reyhaneh Roshani ^1,2, Sara Iranprast ^1,2, Ali Khodadadi ^1,2 *

Cited by CrossRef: 19

1- Abdellateif M, Shaarawy S, Kandeel E, El‑Habashy A, Salem M, El‑Houseini M. A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell‑dendritic cell‑based vaccine. Oncol Lett. 2018; [Crossref]

2- Lisovska N. Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development (Review). Oncol Lett. 2022;23(6) [Crossref]

3- Mengmeng Z, Jiacui S, Shanshan D, Yuan Z, Ying Z, Qiuhong L, Dong W, Hui-Ping L. Serum IL-35 Levels Are Associated With Activity and Progression of Sarcoidosis. Front Immunol. 2020;11 [Crossref]

4- He Q, Jamalpour M, Bergquist E, Anderson R, Gustafsson K, Welsh M. Mouse Breast Carcinoma Monocytic/Macrophagic Myeloid-Derived Suppressor Cell Infiltration as a Consequence of Endothelial Dysfunction in Shb-Deficient Endothelial Cells Increases Tumor Lung Metastasis. IJMS. 2021;22(21):11478 [Crossref]

5- Chen X, Shao Q, Hao S, Zhao Z, Wang Y, Guo X, He Y, Gao W, Mao H. CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function. Oncotarget. 2017;8(8):13703 [Crossref]

6- Majidinia M, Yousefi B. DNA repair and damage pathways in breast cancer development and therapy. DNA Repair. 2017;54:22 [Crossref]

7- Naz A, Aslam M, Khan A, Rasul S, Manzoor H, Iqbal R, Shehzad A, Ali M. Genetic polymorphism in association with susceptibility to tuberculosis: a study in a Pakistani population. Braz J Microbiol. 2019;50(2):429 [Crossref]

8- Yi P, Yu W, Xiong Y, Dong Y, Huang Q, Lin Y, Du Y, Hua F. IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment. 2024;23(2):148 [Crossref]

9- Teymouri M, Pirro M, Fallarino F, Gargaro M, Sahebkar A. IL‐35, a hallmark of immune‐regulation in cancer progression, chronic infections and inflammatory diseases. Intl Journal of Cancer. 2018;143(9):2105 [Crossref]

10- Li X, Singh K, Luo Z, Mejia-Cordova M, Jamalpour M, Lindahl B, Zhang G, Sandler S, Welsh M. Pro-tumoral immune cell alterations in wild type and Shb-deficient mice in response to 4T1 breast carcinomas. Oncotarget. 2018;9(27):18720 [Crossref]

11- Wu W, Jiang H, Li Y, Yan M. IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients. 2017;13(5):3303 [Crossref]

12- Yazdani Z, Rafiei A, Golpour M, Zafari P, Moonesi M, Ghaffari S. IL‐35, a double‐edged sword in cancer. J of Cellular Biochemistry. 2020;121(3):2064 [Crossref]

13- Hashemi V, Maleki L, Esmaily M, Masjedi A, Ghalamfarsa G, Namdar A, Yousefi M, Yousefi B, Jadidi-Niaragh F. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. International Immunopharmacology. 2020;78:106087 [Crossref]

14- Zhao Z, Chen X, Hao S, Jia R, Wang N, Chen S, Li M, Wang C, Mao H. Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine. 2017;89:76 [Crossref]

15- Lisovska N, Shanazarov N. Tumor progression mechanisms: Insights from the central immune regulation of tissue homeostasis (Review). Oncol Lett. 2019; [Crossref]

16- BAYKAL A, TURNA Ö. Current invasive and non-invasive biomarkers in canine mammary tumors. 2021;5(1):39 [Crossref]

17- Akcan U, Karabulut S, İsmail Küçükali C, Çakır S, Tüzün E. Bipolar disorder patients display reduced serum complement levels and elevated peripheral blood complement expression levels. Acta Neuropsychiatr. 2018;30(2):70 [Crossref]

18- Mirjačić Martinović K, Vuletić A, Mališić E, Srdić-Rajić T, Tišma Miletić N, Babović N, Jurišić V. Increased circulating TGF-β1 is associated with impairment in NK cell effector functions in metastatic melanoma patients. Growth Factors. 2022;40(5-6):231 [Crossref]

19- E. EL-HOUSEINI M, S. ARAFAT M, M. EL-HUSSEINY A, M. KASEM I, M. KAMEL M, H. EL-HABASHY A, M. KHAFAGY M, M. RADWAN E, H. HELAL M, S. ABDELLATEIF M. Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study). 2021;29(5):319 [Crossref]